<DOC>
	<DOCNO>NCT00800930</DOCNO>
	<brief_summary>Shigellosis one major cause morbidity mortality many develop country . The continued emergence antibiotic resistant strain complicate treatment shigellosis increase cost treatment markedly . Antimicrobial peptide consider endogenous antibiotic . A mixture antimicrobial peptide ( LL-37 beta-defensin ) drench mucosal epithelial surface form barrier invade microorganism . Recently , find Shigella down-regulates expression LL-37 beta-defensin 1 ( HBD-1 ) colon patient acute shigellosis thereby facilitate bacterial invasion . Both LL-37 HBD-1 could inhibit growth various microbe e.g . S. dysenteriae type 1 , S. flexneri , S. boydii . Our study indicate bacterial DNA might potential mediator down- regulation vitro . Down-regulation LL-37 HBD-1 also see watery diarrhea cause pathogen . Thus , bacteria-mediated down-regulation front line defense could one strategy evolve pathogen subvert host-defense mechanism . gene encode LL-37 culture epithelial cell line up-regulated treated butyrate ; butyrate decrease severity Shigella infection rabbit model . We could reproduce finding human i.e . downregulation CAP-18 ( rabbit homologue human LL-37 ) colon epithelia infection Shigella flexneri . CAP-18 reappeared treatment infect rabbit sodium butyrate . Thus , rabbit model demonstrate proof principal . In study , aim ass efficacy sodium butyrate enema reduction clinical symptom / severity , reduction inflammatory response induction endogenous antibiotic activity rectum adult patient shigellosis .</brief_summary>
	<brief_title>Therapeutic Induction Endogenous Antibiotics</brief_title>
	<detailed_description>Study design : A double blind randomize clinical trial subsequent follow-up . Study Subjects : Adult male female patient attend Clinical Research Service Center ( CRSC ) ICDDR , B Matlab Hospital screen participation study . Randomization : According computer-generated randomization list , patient full fill entry criterion randomize either intervention group ( Pivmecellinam plus butyrate enema ) control group ( Pivmecellinam plus normal saline enema ) . Butyrate enema contain 80 mmol/L butyrate normal saline ( pH 7.2 ) . Placebo enema contain normal saline ( pH 7.2 ) Case management : After enrollment , patient admit study ward ICDDRB Dhaka Matlab hospital . A standard clinical history clinical examination perform one investigator study physician . All patient receive Pivmecillinam , 400 mg , 8 hourly 5 day . The intervention group receive butyrate enema 80 ml 80 mM sodium butyrate , 12 hourly 72 hour placebo group get 80 ml normal saline 12 hourly 72 hour . All patient receive usual hospital food three time day ( breakfast , lunch supper ) . The patient remain study ward 5 day enable identification relapse case . Procedure butyrate enema : Patients instruct lie bed ( cholera cot ) leave lateral position . A soft rectal catheter introduce nurse/physician , 80 ml butyrate solution instill slowly 50 ml plastic syringe . Patients ask retain enema least ½ hour remain supine 30 minute administration . However , patient retain enema 30 minute , give second round enema immediately defecation . Definition clinical cure : A patient define clinically cured day-3 , blood mucus observe stool , ≤ 3 unformed stool 24 hour fever ( oral temperature &gt; 37.5° C ) record . Treatment failure : A patient consider treatment failure day 3 one following feature present : &gt; 3 unformed stool 24 hour , presence blood stool presence fever ( oral temperature &gt; 37.5° C ) . Collection Samples : Patients request stay hospital least 5 day facilitate disease monitor sample . On admission day ( patient enrol serological confirmation slide agglutination test subsequent day i.e . day-1 ) , stool specimen collect patient every day start day admission till 4 day admission . Rectal biopsy sample collect day admission 7 day admission patient enrol Dhaka hospital . Three mL blood collect admission measurement C-reactive protein ( CRP ) use indicator monitor magnitude inflammation . 1 mL blood patient collected measure CRP serum 4th day admission . Stool : Fresh stool sample collect routine microscopic examination parasites cyst well RBC , pu cell macrophage . Stool sample also test measure bacterial counts/load . In brief , 1 g stool dilute normal saline ( 1:10 ) , vortex-mixed 5 min , follow serial dilution 1:10 normal saline plat MacConkey agar plate . After overnight incubation 37ºC , bacterial cfu count . Fresh stool specimen also extract describe earlier measure LL-37 , human beta-defensin 1 3 proinflammatory cytokine ( interleukin-8 1beta ) ELISA method . Rectal biopsy : Rectal biopsy sample obtain patient ( Dhaka Hospital ) .</detailed_description>
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Butyric Acid</mesh_term>
	<criteria>1855 year age duration diarrhoea 04 day cultureconfirmed Shigella spp ( Shigella spp ) stool enrolment receive antimicrobial treatment attend ICDDR , B hospital clinical symptom concomitant infection ( chronic respiratory infection , concomitant gastrointestinal infection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Shigellosis</keyword>
	<keyword>sodium butyrate</keyword>
	<keyword>antimicrobial peptide</keyword>
	<keyword>LL-37</keyword>
	<keyword>innate immunity</keyword>
	<keyword>The aim assess efficacy sodium butyrate enema</keyword>
	<keyword>mark improvement clinical feature</keyword>
	<keyword>endoscopic finding</keyword>
	<keyword>histological feature</keyword>
	<keyword>Induction LL-37 rectum .</keyword>
</DOC>